Blood-vessel-on-chip technology can mimic the hypercoagulability in COVID-19 patients.
ID
Bron
Verkorte titel
Aandoening
COVID-19
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Percentage of endothelial surface in the blood-vessel-on-chip model that is covered by platelets and fibirn ("clotting") upon treatment with COVID-19 patient plasma. Coverage in the blood-vessel-on-chip will be measured by fluorescence microscopy.
Achtergrond van het onderzoek
Initial reports from China (Zhou et al. , Guan et al.) showed an increase of coagulation activation. These first reports showed:
- Higher d-dimer levels
- Medium prolonged prothrombin time
- Mild thrombocytopenia
During the first COVID wave in the months March and April, several reports showed a high incidence of the development of venous thromboembolism (VTE). For example, Middeldorp et al. showed a cumulative incidence of VTE at 21 days of follow-up was 42% (95% CI 30-54).
This protombotic state contributes in the clinical course of COVID-19 patients. For example, Whichman et al. show that thrombotic complications could lead to a severe clinical outcome in COVID-19 patients.
Despite the evidence that shows the presence of this relation between COVID-19 and coagulation complications, the specific interactions are not yet known.
Therefore we aim to develop an in-vitro model, Blood-vessel-on-chip, that can mimic COVID-19 related hypercoagulability. We also intend to use these models in evaluating new antithrombotic treatments.
Doel van het onderzoek
Blood-vessel-on-chip technology can mimic the hypercoagulability in COVID-19 patients.
Onderzoeksopzet
The primary outcome will be measured using fluorescent microscopy.
The secondary outcome will be measured via several laboratory procedures, such as ELISA.
Onderzoeksproduct en/of interventie
Blood taking procedure (total amount of 22.1 mL blood)
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Age of 18 years or older
- A suspected SARS-CoV-2 virus infection
- Need for oxygen supplementation
- CRP level > 50 mg/L
- D-dimer level > 0.5 mg/L
- Ability to provide written informed consent
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- History of venous thromboembolism
- Use of anticoagulant therapy at inclusion
- Known hereditary or acquired thrombophilia
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL9211 |
| Ander register | METC AMC : METC 2020_256 |